TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22733948
Drug: One-dose TEA
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose TEA group (10 mg/kg intra-operatively)
Study: 22733948
Drug: Two-dose TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose TEA group (10 mg/kg pre-operatively and intra-operatively)
Study: 18274163
Drug: Weekly nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly nutrition education based on the nutrition triangle concept of UNICEF for 6 months
Study: 14530690
Drug: Degassed aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degassed aqueous solution made of 40 ml of water and 10 ml of dimethicone emulsion (1 ml/100 mg)
Study: 1406817
Drug: Tacrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (10 or 20 mg four times a day)
Study: 6428371
Drug: Haloperidol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1.0 to 6.0 mg/day)
Study: 6428371
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (500 to 2,000 mg/day)
Study: 24641941
Drug: Olokizumab (OKZ)
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olokizumab (OKZ) 60 mg
Study: 24641941
Drug: Olokizumab (OKZ)
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olokizumab (OKZ) 120 mg
Study: 24641941
Drug: Olokizumab (OKZ)
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olokizumab (OKZ) 240 mg
Study: 24641941
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 8 mg/kg Q4W
Study: 22522225
Drug: Lopinavir-ritonavir (400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir (400mg and 100mg respectively) administered after a moderate-fat breakfast
Study: 22522225
Drug: Coprandial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coprandial administration of formulations
Study: 24636673
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus extended-release dipyridamole
Study: 10613628
Drug: Graded workload
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded workload treadmill protocol (G-test; 2 mph; 0% grade, increasing 2% every 2 min)
Study: 10613628
Drug: Graded workload
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded workload treadmill protocol (G-test)
Study: 2015162
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg three times daily for 10 days)
Study: 7159883
Drug: procainamide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: procainamide 1.0 g t.i.d.
Study: 7159883
Drug: disopyramide 150
Normalized name: disopyramide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: disopyramide 150 mg t.i.d.
Study: 29108096
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Substance Abuse-Domestic Violence (SADV)
Study: 25185754
Drug: 6:1‐OM3 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6:1‐OM3 (4 g/day)
Study: 25185754
Drug: 6:1‐OM3 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6:1‐OM3 (4 g/day) in hypertriglyceridemic subjects
Study: 17594926
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg once daily
Study: 16275811
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus a 15-session group cognitive therapy prevention program (n = 45)
Study: 2909288
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg/m2 1 hour before CDDP administration
Study: 2909288
Drug: No diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diuretic drug (Control)
Study: 31286728
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding (at specific acupoints), once every two weeks, six times as a course of treatment, until 12 weeks into pregnancy.
Study: 31286728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with intramuscular injection of progesterone (40 mg) once every day.
Study: 28111716
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab (250 mg/m2 given twice 1 week apart per cycle)
Study: 28111716
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with low-dose rituximab
Study: 28111716
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of low-dose rituximab
Study: 28111716
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or more cycles of low-dose rituximab
Study: 24723493
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab
Study: 25988270
Drug: Real Auricular
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real Auricular Point Acupressure (APA) treatment
Study: 25988270
Drug: Sham Auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Auricular Point Acupressure treatment
Study: 24120678
Drug: 2+1-dose group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2+1-dose group (PCV7 at 2, 4, and 11 months)
Study: 24120678
Drug: 2-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose group (PCV7 at 2 and 4 months)
Study: 24120678
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose at 24 months
Study: 21611896
Drug: Tongjiang granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongjiang granule (TJG) 10 g and mosapride citrate dummy 5 mg three times a day
Study: 21611896
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate 5 mg and TJG dummy 10 g three times a day
Study: 16687481
Drug: Salbutamol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (12 mg/day for four weeks)
Study: 16086881
Drug: China-made tropisetron
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: China-made tropisetron hydrochloride (5 mg, intravenously)
Study: 10608948
Drug: Liquid nutrition
Normalized name: Liquid Nutrition Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid nutrition supplement (six 235‐mL cans weekly)
Study: 2125513
Drug: Neutron treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron treatment
Study: 2125513
Drug: Photon treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon treatment
Study: 295576
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of L-asparaginase
Study: 295576
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of L-asparaginase
Study: 24667715
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (EndoTAG‐1 22 mg/m(2) + paclitaxel 70 mg/m(2))
Study: 24667715
Drug: EndoTAG‐1 (2×
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoTAG‐1 (2× 44 mg/m(2))
Study: 24667715
Drug: Paclitaxel (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (90 mg/m(2))
Study: 21756154
Drug: Combination formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination formulation (5% hexane extract of Curcuma aeruginosa + 5% minoxidil)
Study: 16837516
Drug: Activating, structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activating, structured treatment by social workers
Study: 12539884
Drug: Eucarbon (charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucarbon (charcoal tablets)
Study: 9424977
Drug: Famciclovir, 500
Normalized name: Famciclovir, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir, 500 mg orally twice daily for 8 weeks
Study: 7656833
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose DDP (Cisplatin)
Study: 7656833
Drug: Fractionated low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated low doses DDP (Cisplatin)
Study: 2569959
Drug: Betaxolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (20 mg/day)
Study: 2569959
Drug: Minoxidil (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil (5.5 mg/day, added at week 6 if SDAP > 95 mm Hg)
Study: 27894198
Drug: 27 mg
Normalized name: aspirin 227 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 mg elemental iron daily (group I)
Study: 27894198
Drug: 54 mg
Normalized name: aspirin 454 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg elemental iron daily (group II)
Study: 25301007
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care interventions developed by the clinical pharmacist in collaboration with the physician
Study: 25301007
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care interventions
Study: 24189342
Drug: Fluoxetine, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, 40 mg per day for 3 weeks
Study: 15468944
Drug: Iodine concentration
Normalized name: iodine Topical Solution [QuarterMate Concentrate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine concentration of 370 mg/mL (Group B)
Study: 15468944
Drug: Iodine concentration
Normalized name: iodine Topical Solution [QuarterMate Concentrate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine concentration of 300 mg/mL (Group A)
Study: 9630813
Drug: Salofalk (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salofalk (500 mg)
Study: 9630813
Drug: Pentasa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa (500 mg)
Study: 8310405
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (1 gm cephalothin intravenously 30 minutes before the procedure and 500 mg cephalexin orally every 6 hours for 3 days afterward)
Study: 21703048
Drug: Tadalafil plus
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil plus Vacuum Erection Device (VED), 10 minutes unbanded per day for at least 5 days weekly
Study: 16093403
Drug: Powdered fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered fermented milk with L. helveticus CM4 (12 g daily for 4 weeks)
Study: 16093403
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 g daily for 4 weeks)
Study: 10442275
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide at a dose of 2,400 micrograms daily
Study: 10442275
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid (standard adjunctive therapy)
Study: 7792016
Drug: Hyperuricemia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperuricemia group with triglycerides > 200 mg/dl
Study: 2217030
Drug: Lornoxicam 4
Normalized name: lornoxicam 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 4 mg twice daily
Study: 24434887
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy exercise program (3 months)
Study: 20933640
Drug: Sequential multidetector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential multidetector CT (MDCT)
Study: 1541613
Drug: Single 800-centigray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 800-centigray dose of limited-field radiation
Study: 1541613
Drug: 1000 centigray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 centigray of limited-field radiation in divided doses
Study: 3993426
Drug: Iohexol 350
Normalized name: iohexol 350 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 350 mg I/ml, 500 mg I/kg body weight
Study: 3993426
Drug: Metrizoate 350
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrizoate 350 mg I/ml, 500 mg I/kg body weight
Study: 29935583
Drug: Dexmedetomidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.5 ng ml‐1)
Study: 29935583
Drug: Propofol (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.7 μg ml‐1)
Study: 29935583
Drug: S-ketamine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.75 μg ml‐1)
Study: 27142970
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (IV group)
Study: 24262818
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) plus usual care
Study: 18062586
Drug: Hypocalcaemia during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocalcaemia during treatment
Study: 8918628
Drug: Non-Epo treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-Epo treatment
Study: 8918628
Drug: Epo treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epo treatment
Study: 1323587
Drug: MK-571 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (450 mg total dose)
Study: 1323587
Drug: MK-571 (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (37.5 mg total dose)
Study: 6381167
Drug: Ibuprofen 1600
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1600 mg daily
Study: 6381167
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg daily
Study: 28965385
Drug: Modified Jujing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Jujing No.2 Decoction (1 dose a day, bid)
Study: 28965385
Drug: Danshen Tablets
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen Tablets (4 tablets once, tid) plus Liu Wei Di Huang Wan (8 pills once, tid)
Study: 23743404
Drug: Sapropterin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin (10 mg/kg)
Study: 19536889
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade (CAB) with LHRH-A plus bicalutamide 80 mg
Study: 19536889
Drug: LHRH-A monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH-A monotherapy
Study: 11770031
Drug: Steroid (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (250 mg of prednisolone)
Study: 11770031
Drug: Heparin coating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin coating of the artificial surface (Bioline)
Study: 7946230
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication (control group)
Study: 2829953
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Fenoterol and Salbutamol)
Study: 12472583
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of micronized 17beta‐oestradiol (E2)
Study: 12472583
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of micronized 17beta‐oestradiol + 10 mg dydrogesterone (E2 + D)
Study: 9506490
Drug: Triamcinolone diacetate,
Normalized name: triamcinolone diacetate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone diacetate, 40 mg intramuscular (i.m.)
Study: 9506490
Drug: Prednisone, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 40 mg/day orally for 5 days
Study: 7922010
Drug: Buffy coat
Normalized name: Leucocyte buffy coat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffy coat preparation method with yield-enhancing change
Study: 7922010
Drug: Allogeneic marrow
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic marrow infusion
Study: 3049173
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% bifonazole cream
Study: 11288030
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone (NAL) infusion (1.6 mg/h for 2.5 hours) during GHRH testing
Study: 30408100
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tests of ET function
Study: 22469877
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy program (25 mins, twice a day, five times a week, for 4 weeks)
Study: 22469877
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy program
Study: 17567301
Drug: Adapalene gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene gel, 0.1% once daily (QD)
Study: 17567301
Drug: Adapalene gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene gel, 0.1% every other day (QoD)
Study: 15692069
Drug: ABO-compatible platelets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABO-compatible platelets, stored for 48 hours or less, large doses of platelets
Study: 15692069
Drug: Filtered apheresis
Normalized name: FILTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtered apheresis platelets, increased dose of platelets transfused
Study: 15692069
Drug: Heparin administration,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration, fever, bleeding, increasing number of platelet transfusions, increasing weight, at least 2 pregnancies, male gender
Study: 15692069
Drug: Lymphocytotoxic antibody
Normalized name: Lymphocytotoxic antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocytotoxic antibody positivity
Study: 7751898
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (RA) 45 mg/m2 orally twice per day for 14 days (Cycle 1)
Study: 7751898
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (RA) 45 mg/m2 orally twice per day for 14 days plus ketoconazole 400 mg orally for one dose, then 200 mg orally three times per day for 14 days (Cycle 2)
Study: 12496753
Drug: Ketoconazole administration
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole administration
Study: 27125966
Drug: Hormone Manipulation
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Manipulation (HM; tamoxifen or LHRH agonists)
Study: 27125966
Drug: Hormone Manipulation
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Manipulation (HM; tamoxifen or LHRH agonists) in ER+/unknown disease
Study: 27125966
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment groups (FE50C-HM, FE50C+HM, FE75C-HM, FE75C+HM)
Study: 22296781
Drug: Insulin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (daily bedtime subcutaneous NPH insulin)
Study: 22296781
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (oral hypoglycemic agents)
Study: 17619859
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rimonabant daily for 15 days
Study: 17619859
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg rimonabant on day 15 after 14 days of placebo
Study: 11573666
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil 20 microg combined with morphine 200 microg
Study: 11573666
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil and morphine
Study: 9757881
Drug: Systemic methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic methotrexate therapy
Study: 28689102
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (1 dose of 1 g IV) once a month for 12 months
Study: 25142619
Drug: Systemic Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Family Therapy (alternate form)
Study: 8943170
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) 1750 anti-Xa IU daily
Study: 8943170
Drug: Standard unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard unfractionated heparin (UFH) 5000 IU twice a day
Study: 1586105
Drug: Nal‐Glu (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal‐Glu (GnRH antagonist) for 6 weeks
Study: 1586105
Drug: Nal‐Glu plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal‐Glu plus testosterone enanthate (100 mg/wk)
Study: 4026044
Drug: Almitrine 50
Normalized name: almitrine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 50 mg orally twice a day for 14 days
Study: 26595549
Drug: SRT2104 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 50 mg daily
Study: 26595549
Drug: SRT2104 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 500 mg daily
Study: 26595549
Drug: SRT2104 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (both doses)
Study: 20368196
Drug: Intensified glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified glucose control based on insulin (I-group)